The Cigna Group Foundation Supports More Than 8,000 Veterans Through Community-Led Housing Stability Programs Accessibility StatementSkip Navigation BLOOMFIELD, Conn., March 24, 2026 /PRNewswire/ -- The Cigna Group Foundation, the philanthropic arm of The Cigna Group (NYSE: CI), today released its 2025 Improving Veteran Mental Health Impact Report, highlighting the collective progress that its 22 nonprofit partners have made in supporting 8,000 veterans by expanding access to stable housing and providing in ...

Group 1 - The primary goal of the "High Income DIY Portfolios" service is to provide high income with low risk and capital preservation for DIY investors [1] - The service offers six different portfolios tailored for various income-seeking investors, including retirees or near-retirees [1] - The portfolios include two High-Income portfolios, a Dividend Growth Investing (DGI) portfolio, a conservative strategy for 401K accounts, a Sector-Rotation strategy, and a High-Growth portfolio [1] Group 2 - The "High Income DIY Portfolios" service includes a total of 10 model portfolios with varying income targets and risk levels, along with buy and sell alerts and live chat support [2] - The investment approach focuses on dividend-growing stocks with a long-term horizon, aiming for lower drawdowns and sustainable yields [2] - The service is designed to help investors create stable, long-term passive income [2]

Core Viewpoint - Bernstein upgraded The Cigna Group (NYSE:CI) from "Market Perform" to "Outperform" with a price target of $358, driven by expected increases in stock multiples due to regulatory changes and economic guidance [2]. Group 1: Analyst Upgrades and Projections - Analysts at Bernstein expect the stock's multiple to increase over time, citing the Pharmacy Benefit Manager reform bill and the FTC settlement as key drivers of investor confidence [2]. - EPS estimates for 2027-2030 were slightly raised, while the 2026 estimate remained unchanged [2]. Group 2: Financial Projections - The Cigna Group reiterated its 2026 projection, estimating consolidated adjusted income from operations of at least $30.25 per share [3]. - Management emphasized stability across major sectors, projecting Evernorth's pre-tax adjusted income from operations of at least $6.9 billion and Cigna Healthcare's pre-tax adjusted income from operations of at least $4.5 billion [3]. Group 3: Leadership Changes - Analysts at JPMorgan Chase & Co. noted the surprise retirement of CEO Cordani but expressed confidence in the new leadership under CEO Brian Evanko [4]. - The Cigna Group operates as a global provider of health services, offering pharmacy benefit management, specialty pharmacy, care delivery, and medical insurance solutions through its Evernorth Health Services and Cigna Healthcare segments [4].

Core Insights - Cigna Group (CI) is a global health company offering a range of health solutions and insurance products through two main segments: Cigna Healthcare and Evernorth Health Services [1] Financial Performance - Cigna has a market capitalization of $68.8 billion and its shares have decreased by 3.4% year to date, outperforming the industry average decline of 13.5% [2] - The forward P/E ratio stands at 8.61x, which is lower than the industry average of 13.45x, indicating a relatively attractive valuation [2] - The Zacks Consensus Estimate for 2026 earnings is $30.29 per share, reflecting a 1.5% year-over-year increase, with revenues estimated at $284.4 billion, indicating 3.5% year-over-year growth [3] Growth Drivers - Cigna's adjusted income from operations for 2025 rose by 4% year over year, primarily driven by growth in the Evernorth Health Services segment, which saw adjusted revenues increase by 16% to $235 billion [4] - The company expects adjusted operating income to reach at least $7.95 billion in 2026 [4] Cost Management and Innovations - The adjusted SG&A expense ratio was reduced to 5.0% in 2025 due to business mix shifts and ongoing digital transformation [5] - Evernorth Health Services introduced a new pharmacy benefits model that directly passes drug manufacturer discounts to customers, lowering out-of-pocket costs, with plans for Cigna Healthcare to adopt this model in 2027 [5] Shareholder Value Initiatives - Cigna repurchased 11.9 million shares for approximately $3.6 billion in 2025 and increased its quarterly dividend to $1.56 per share in early 2026 from $1.51 in 2025, indicating confidence in long-term cash flow [6] Debt and Financial Health - Cigna's long-term debt was $30.9 billion at the end of 2025, significantly higher than its cash balance of $7.7 billion, which may pressure interest expenses going forward [10]

Core Viewpoint - The article compares CVS Health and Cigna Group as potential investments for retirement portfolios, highlighting the trade-offs between stability and income versus stronger earnings quality and capital discipline. Valuation - CVS Health trades at 11.3x trailing adjusted earnings, while Cigna trades at 9.4x, making Cigna cheaper on key metrics. Cigna's 2026 adjusted EPS guidance is at least $30.25, translating to a forward multiple of approximately 9.3x, compared to CVS's 10.7x using a midpoint of $7.10 for 2026 adjusted EPS. Cigna's net income grew 73.47% year-over-year to $5.957 billion, while CVS's net income fell 62.55% to $1.728 billion due to a $5.7 billion goodwill impairment and $1.2 billion in legacy litigation charges [1]. Yield and Income - CVS offers a quarterly dividend of $0.665, annualized to $2.66, resulting in a yield of approximately 3.5%. Cigna's dividend has increased from $1.00 per quarter in 2021 to $1.56 per quarter, with a current yield of roughly 2.3% at a price of $265.88. CVS has a revenue base of $402 billion and operating cash flow of $10.639 billion for FY2025 [1]. Long-Term Track Record and Growth Trajectory - Cigna has consistently beaten adjusted EPS estimates in all four quarters of 2025, with a 17% revenue growth in its Evernorth Health Services segment and an improvement in SG&A ratio from 5.9% to 5.0%. Cigna repurchased 11.9 million shares for approximately $3.6 billion in 2025. CVS reported a 9.7% increase in same-store prescription volume and a 12.4% growth in Pharmacy & Consumer Wellness revenue to $37.66 billion, but its operating income fell 45.28% year-over-year [1]. Price Performance - Over the past year, CVS's stock is up 17.32%, while Cigna's is down 14.51%. However, over a decade, Cigna has returned 101.36%, compared to CVS's 1.84% [1]. Conclusion - For retirees prioritizing current income, CVS may be appealing due to its higher yield and growth in the pharmacy business. However, for those focused on long-term wealth accumulation, Cigna is viewed as the stronger investment due to its lower earnings multiple, consistent execution, and significant historical returns [1].

Core Insights - The Cigna Group (NYSE:CI) announced a leadership change with CEO David Cordani retiring and being succeeded by Brian Evanko, which may surprise some investors given the timing amid a significant transformation in the company's business model [3][4] - Despite a stock decline of over 15% in the past year, Cigna's current trading price of $269.66 suggests a potential upside of 23.67%, outperforming the healthcare plans sector which fell by more than 30% [2] - Analysts remain optimistic, with nearly 85% maintaining a bullish outlook as of March 9, 2026, reflecting confidence in the company's strategic continuity [2] Leadership Change - CEO David Cordani's retirement was announced on March 3, 2026, with Brian Evanko, the former CFO and current COO, taking over as CEO [3] - Evanko is noted for his extensive institutional experience and is expected to be one of the youngest CEOs in the healthcare services industry [3] Financial Outlook - Cigna reaffirmed its 2026 earnings outlook, projecting a consolidated adjusted income from operations of at least $30.25 per share [5] - The company anticipates a pre-tax adjusted income of at least $6.9 billion for Evernorth and at least $4.5 billion for Cigna Healthcare [5] Business Model Transformation - Cigna is entering the first year of a multi-year transformation of its pharmacy benefit management (PBM) model, which is a significant change for the company [4]

Upgrades - Bernstein upgraded CVS Health (CVS) to Outperform from Market Perform with a price target of $94, up from $91, indicating a 23% upside due to attractive exposure to the Medicare Advantage turnaround and potential for more stable earnings in its pharmacy businesses after reform impacts [2] - Bernstein upgraded Cigna (CI) to Outperform from Market Perform with a price target of $358, up from $307, as the firm sees the combination of the Pharmacy Benefit Manager reform bill and the FTC settlement as "clearing events" that will increase the multiple over time [2] - Wells Fargo double upgraded Occidental (OXY) to Overweight from Underweight with a price target of $69, up from $47, citing the company's peer-leading oil sensitivity and Permian capital efficiency trends as key factors [2] - Piper Sandler also upgraded Occidental to Overweight from Neutral with a price target of $66, up from $54 [2] - Williams Trading upgraded Crocs (CROX) to Hold from Sell with an $84 price target, citing valuation as the reason for the upgrade with shares currently below the price target [2] - Jefferies upgraded Petco (WOOF) to Buy from Hold with a price target of $5, up from $4.05, noting that the company is entering 2026 with growth prospects as liquidity and profitability concerns are now resolved [2]

Industry Overview - The U.S. health insurance industry, known as Health Maintenance Organization (HMO), is focusing on technological innovation and pursuing mergers and acquisitions (M&A) to enhance capabilities and expand market presence [1][7] - The industry is experiencing rising medical expenses due to deferred care, chronic disease management, and increasing costs of specialty drugs [2][4] - The HMO industry consists of entities that provide basic and supplemental health services, assuming risks and assigning premiums to health insurance policies [3] Trends Impacting the Industry - Escalating medical expenses are driven by delayed medical procedures, increased demand for screenings, and a growing aging population, which is straining the Health Benefit Ratio and profit margins [4] - Regulatory changes, including the One Big Beautiful Bill Act, may tighten Medicaid eligibility and reduce ACA enrollment, impacting membership and reimbursements [5] - A nationwide shortage of healthcare professionals is affecting hospital operations and the quality of care, which could impact customer retention for HMOs [6] Strategic Initiatives - HMOs are increasingly focusing on M&A to broaden capabilities, enter new markets, and enhance their competitive advantage [7][8] - The Federal Reserve's interest rate cuts in 2025 are expected to lower borrowing costs, potentially fueling M&A activity in the industry [8] Industry Performance - The Zacks Medical-HMO industry has underperformed, declining 35.6% over the past year compared to the S&P 500's growth of 24.4% [12] - The industry's current valuation is at a forward P/E ratio of 13.71X, significantly lower than the S&P 500's 22.01X and the sector's 20.66X [15] Company Highlights - **UnitedHealth Group**: Revenue growth is supported by strong performance in its UnitedHealthcare and Optum segments, with a 2026 earnings estimate of $17.70 per share, indicating 8.3% growth [20][21] - **Cigna**: Thrives on the performance of its Evernorth and Cigna Healthcare platforms, with a 2026 earnings estimate of $30.29 per share, reflecting 1.5% growth [24][25] - **Humana**: Achieves consistent growth through higher premium revenues and a strong membership base, with a 2026 earnings estimate of $9.82 per share, indicating significant growth potential [29][30] - **Centene**: Revenue growth is driven by its Medicare and Medicaid businesses, with a 2026 earnings estimate of $3.01 per share, suggesting a 44.7% rise from the previous year [33][34]

Core Insights - Cigna (CI) reported strong results for Q4 and the full year 2025, surpassing consensus forecasts for both revenue and EPS [1] - The company maintained a high operating margin, indicating robust operational efficiency [1] Financial Performance - Cigna's revenue and EPS exceeded market expectations, showcasing the company's strong financial health [1] - The operating margin remained stable at a high level, reflecting effective cost management and operational performance [1]

Core Viewpoint - Cigna is undergoing a strategic shift in its business model, focusing on rebate-free pharmacy benefit services, which is expected to enhance compliance and reshape public perception of pharmacy benefit managers [1][3]. Group 1: Price Target Adjustment - Piper Sandler has reduced its price target for Cigna from $374 to $370 while maintaining an Overweight rating, emphasizing the importance of the rebate-free pharmacy benefit services model in Cigna's strategy [1]. Group 2: Leadership Transition - Cigna's long-time CEO David Cordani is set to retire and transition to the role of executive chair on July 1, with Brian Evanko, a veteran executive, taking over as CEO [2]. Group 3: Business Model Changes - Cigna is shifting some customers to a model that eliminates after-market discounts (rebates), which management anticipates will pressure margins over the next two years [3]. - The company has previously made significant acquisitions, including the $54 billion purchase of Express Scripts in 2018, and divested its Medicare Advantage business last year [3]. Group 4: Company Overview - Cigna operates as a global health company with two primary growth platforms: Evernorth Health Services and Cigna Healthcare, focusing on coordinated health solutions [4].